Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates

References

• Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 351: 1860–1873
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles R. Multiple myeloma. Lancet 2004; 363: 875–887
   PubMed Web of Science ®Google Scholar
• Harrison S J, Cook G. Immunotherapy in multiple myeloma—possibility or probability?. Br J Haematol 2005; 130: 344–362
   PubMed Web of Science ®Google Scholar
• Tricot G, Vesole D H, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196–1198
   PubMed Web of Science ®Google Scholar
• Perez-Simon J A, Martino R, Alegre A, Tomas J F, De Leon A, Caballero D, et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104–108
   PubMed Web of Science ®Google Scholar
• Kwak L W, Taub D D, Duffey P L, Bensinger W I, Bryant E M, Reynolds C W, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016–1020
   PubMed Web of Science ®Google Scholar
• Bergenbrant S, Yi Q, Osterborg A, Bjorkholm M, Osby E, Mellstedt H, et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 1996; 92: 840–846
   PubMed Web of Science ®Google Scholar
• Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998; 91: 2459–2466
   PubMed Web of Science ®Google Scholar
• Wen Y J, Ling M, Bailey-Wood R, Lim S H. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998; 4: 957–962
   PubMed Web of Science ®Google Scholar
• Lim S H, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999; 83: 215–222
   PubMed Web of Science ®Google Scholar
• Reichardt V L, Okada C Y, Liso A, Benike C J, Stockerl-Goldstein K E, Engleman E G, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma–a feasibility study. Blood 1999; 93: 2411–2419
   PubMed Web of Science ®Google Scholar
• Lim S H, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999; 83: 215–222
   PubMed Web of Science ®Google Scholar
• Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998; 91: 2459–2466
   PubMed Web of Science ®Google Scholar
• Wen Y J, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 2002; 99: 3280–3285
   PubMed Web of Science ®Google Scholar
• Garderet L, Mazurier C, Pellat-Deceunynck C, et al. Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma. Leuk Lymphoma 2006; 47: 1340–1347
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003; 102: 1435–1442
   PubMed Web of Science ®Google Scholar
• Milazzo C, Reichardt V L, Muller M R, Grunebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003; 101: 977–982
   PubMed Web of Science ®Google Scholar
• Qian J, Wang S, Yang J, Xie J, Lin P, Freeman M E, et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res 2005; 11: 8808–8815
   PubMed Web of Science ®Google Scholar
• Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 2002; 99: 2512–2517
   PubMed Web of Science ®Google Scholar
• Raje N, Hideshima T, Davies F E, Chauhan D, Treon S P, Young G, et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 2004; 125: 343–352
   PubMed Web of Science ®Google Scholar
• Hao S, Bi X, Xu S, Wei Y, Wu X, Guo X, et al. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Exp Oncol 2004; 26: 300–306
   PubMed Web of Science ®Google Scholar
• Vasir B, Borges V, Wu Z, Grosman D, Rosenblatt J, Irie M, et al. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol 2005; 129: 687–700
   PubMed Web of Science ®Google Scholar
• Lee J J, Takei M, Hori S, Inoue Y, Harada Y, Tanosaki R, et al. The role of PGE(2) the differentiation of dendritic cells: how do dendritic cells influence T-cell polarization and chemokine receptor expression?. Stem Cells 2002; 20: 448–459
   PubMed Web of Science ®Google Scholar
• Lee J J, Nam C E, Nam J H, Lee H C, Chung I J, Park M S, et al. Generation of cytotoxic donor CD8+ T cells against relapsing leukemic cells following allogeneic transplantation by stimulation with leukemic cell- or leukemic lysate pulsed donor cell-derived dendritic cells. Leuk Res 2004; 28: 517–524
   PubMed Web of Science ®Google Scholar
• Lee J J, Kook H, Park M S, Nam J H, Choi B H, Song W H, et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher 2004; 19: 66–70
   PubMed Web of Science ®Google Scholar
• Lee J J, Choi B H, Nam J H, Park M S, Song W H, Yang D H, et al. The generation of leukemic dendritic cells from acute myeloid leukemia cells is potentiated by the addition of CD40L at the terminal maturation stage. J Clin Apher 2004; 19: 130–136
   PubMed Web of Science ®Google Scholar
• Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991; 14: 185–192
   Web of Science ®Google Scholar
• Mailliard R B, Lotze M T. Dendritic cells prolong tumor-specific T-cell survivial and effector function after interaction with tumor targets. Clin Cancer Res 2001; 7(Suppl)980s–988s
   PubMed Web of Science ®Google Scholar
• Fiore F, Nuschak B, Peola S, Mariani S, Muraro M, Foglietta M, et al. Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. Eur J Immunol 2005; 35: 1155–1163
   PubMed Web of Science ®Google Scholar
• Lee J J, Park M S, Park J S, Kang H K, Kim S K, Nguyen Pham T N, et al. Induction of leukemic-cell-specific cytotoxic T lymphocytes by autologous monocyte-derived dendritic cells presenting leukemic cell antigens. J Clin Apher 2006; 21: 188–194
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100: 230–237
   PubMed Web of Science ®Google Scholar
• Brimnes M K, Svane I M, Johnsen H E. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol 2006; 144: 76–84
   PubMed Web of Science ®Google Scholar